These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9145877)

  • 1. Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers.
    Nix DE; Wilton JH; Hyatt J; Thomas J; Strenkoski-Nix LC; Forrest A; Schentag JJ
    Antimicrob Agents Chemother; 1997 May; 41(5):1108-14. PubMed ID: 9145877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of pharmacokinetics and pharmacodynamics in the design of dosage schedules for 12-h cefotaxime alone and in combination with other antibiotics.
    Nix DE; Schentag JJ
    Diagn Microbiol Infect Dis; 1995; 22(1-2):71-6. PubMed ID: 7587053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic interaction between ofloxacin and cefotaxime against common clinical pathogens.
    Jenkins SG; Lewis JW
    Infection; 1995; 23(3):154-61. PubMed ID: 7499004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro interaction between ofloxacin and cefotaxime against gram-positive and gram-negative bacteria involved in serious infections.
    Gimeno C; Borja J; Navarro D; Valdés L; García-Barbal J; García-de-Lomas J
    Chemotherapy; 1998; 44(2):94-8. PubMed ID: 9551238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum bactericidal activity against Enterobacteriaceae producing broad-spectrum beta-lactamases in volunteers administered ofloxacin and cefotaxime, alone or combined.
    Weber P; Boussougant Y; Farinotti R; Carbon C
    Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):524-6. PubMed ID: 2504593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial interactions (synergy) of teicoplanin with two broad-spectrum drugs (cefotaxime, ofloxacin) tested against gram-positive isolates from Germany and the United States.
    Jones RN; Marshall SA; Grimm H
    Diagn Microbiol Infect Dis; 1997 Oct; 29(2):87-94. PubMed ID: 9368084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum bactericidal activity of levofloxacin against Streptococcus pneumoniae.
    Shah PM
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():61-5. PubMed ID: 10404340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine.
    Chien SC; Chow AT; Rogge MC; Williams RR; Hendrix CW
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1765-9. PubMed ID: 9257757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic interactions of ciprofloxacin, piperacillin, and piperacillin/tazobactam in healthy volunteers.
    Strenkoski-Nix LC; Forrest A; Schentag JJ; Nix DE
    J Clin Pharmacol; 1998 Nov; 38(11):1063-71. PubMed ID: 9824789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of synergy between ofloxacin, ceftazidime, and tobramycin against Pseudomonas aeruginosa.
    Madaras-Kelly KJ; Moody J; Larsson A; Baeker Hovde L; Rotschafer JC
    Chemotherapy; 1997; 43(2):108-17. PubMed ID: 9084919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.
    Chien SC; Wong FA; Fowler CL; Callery-D'Amico SV; Williams RR; Nayak R; Chow AT
    Antimicrob Agents Chemother; 1998 Apr; 42(4):885-8. PubMed ID: 9559801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro activity of three fluoroquinolones, cefotaxime and clindamycin against staphylococci.
    Schumacher-Perdreau F; Peters G
    Zentralbl Bakteriol; 1995 Oct; 282(4):389-93. PubMed ID: 9810661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicentre study of the in-vitro activity of cefotaxime, cefuroxime, ceftazidime, ofloxacin and ciprofloxacin against blood and urinary pathogens.
    Amyes SG; Baird DR; Crook DW; Gillespie SH; Howard AJ; Oppenhiem BA; Pedler SJ; Paull A; Tompkins DS; Lawrie SA
    J Antimicrob Chemother; 1994 Nov; 34(5):639-48. PubMed ID: 7706159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.
    Madaras-Kelly KJ; Ostergaard BE; Hovde LB; Rotschafer JC
    Antimicrob Agents Chemother; 1996 Mar; 40(3):627-32. PubMed ID: 8851583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis.
    Navasa M; Follo A; Llovet JM; Clemente G; Vargas V; Rimola A; Marco F; Guarner C; Forné M; Planas R; Bañares R; Castells L; Jimenez De Anta MT; Arroyo V; Rodés J
    Gastroenterology; 1996 Oct; 111(4):1011-7. PubMed ID: 8831596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic effects of amoxicillin versus cefotaxime against penicillin-susceptible and penicillin-resistant pneumococcal strains: a phase I study.
    Aguilar L; Rosendo J; Balcabao IP; Martín M; Giménez MJ; Frías J; Prieto J
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1389-91. PubMed ID: 9174206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration.
    Hansen E; Bucher M; Jakob W; Lemberger P; Kees F
    Intensive Care Med; 2001 Feb; 27(2):371-5. PubMed ID: 11396281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.
    Preston SL; Drusano GL; Berman AL; Fowler CL; Chow AT; Dornseif B; Reichl V; Natarajan J; Wong FA; Corrado M
    Antimicrob Agents Chemother; 1998 May; 42(5):1098-104. PubMed ID: 9593134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of extremely high penicillin and cefotaxime resistance and high-level levofloxacin resistance in clinical isolates of Streptococcus pneumoniae in Hungary.
    Glatz K; Szabó D; Szabó G; Boriszova D; Rozgonyi F
    J Antimicrob Chemother; 2001 Nov; 48(5):731-4. PubMed ID: 11679565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative serum bactericidal activities of ceftizoxime and cefotaxime against intermediately penicillin-resistant Streptococcus pneumoniae.
    Patel KB; Nicolau DP; Nightingale CH; Quintiliani R
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2805-8. PubMed ID: 9124845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.